According to GlobalData, ENROUTE is one of 14 product lines sold in the US carotid & renal artery stents market; these product lines are sold by 8 different manufacturers. The average selling price for ENROUTE decreased in hospitals, decreased in health systems, and increased outside of hospital facilities in 2022. The price of the ENROUTE device can be viewed in GlobalData’s micro pricing report and can be retrieved according to purchase date, facility type, bed size, and geographical region. Buy the report here.

Smarter leaders trust GlobalData

The selling price or list price of a medical device is driven by numerous factors, such as therapy area and complexity of procedure, level of reimbursement, development costs, the number of competing manufacturers, product life cycle, and whether there have been any recent new technology or product launches.

In addition, the final selling pricing of medical devices is also impacted by the discounting policy of the manufacturer. Companies such as Silk Road Medical apply discounts for their devices based on their internal business strategy, inventory control, and monthly or quarterly sales targets. In addition, sale location can also affect the final selling price of a device, both in terms of geographical region and facility type. Prices for the same medical device often vary in hospitals and health systems versus outside of hospital facilities, for example if high volume healthcare institutions can negotiate discounts or rebates based on large purchase sizes.

Silk Road Medical overview

Silk Road Medical Inc (Silk Road) develops and manufactures medical devices for the treatment of carotid artery diseases. The company’s product portfolio includes the ENROUTE trans carotid neuroprotection system, ENROUTE trans carotid stent system, ENHANCE trans carotid peripheral access kit and ENROUTE 0.014” guidewire. Silk Road focuses to develop therapies for carotid artery disease called trans carotid artery revascularization (TCAR). Its TCAR approach combines surgical principles of neuroprotection with invasive endovascular techniques to treat blockages in the carotid artery at risk of causing a stroke. The company offers products under the brand names Enroute and Enhance. Silk Road is headquartered in Sunnyvale, California, the US.

For a complete picture of ENROUTE, Carotid & Renal Artery Stents pricing in the US, buy the report here.

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Medical Intelligence Center Market Models are the gold standard of medical device market valuation, company share estimation and market trend forecasting. GlobalData uses a patient-based forecast model or installed base methodology to determine the market size for therapeutic indications and capital equipment expenditures. Estimates are based on a number of sources, including primary research—KOL and industry contact interviews—and secondary research, such as company reports, press releases, published articles, proprietary databases, and general news media.